.png){kind=icon}
.png){kind=icon}
Return
Insights from the ESMO Targeted Anticancer Therapies Asia Congress 2026
.png){kind=icon}
PRE
AI
V
DOI：10.1038/s43018-026-01215-1.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
The latest ESMO Targeted Anticancer Therapies Asia Congress brought together researchers, clinicians and industry experts to discuss how advances in molecular oncology, cell therapies, artificial intelligence and translational science are shaping the next generation of cancer treatments. Opening the meeting, European Society For Medical Oncology (ESMO) president Fabrice André highlighted the society’s increasing global reach, with members spanning Europe, Asia and other regions worldwide. He emphasized the ESMO’s mission to support oncology professionals through education, consensus frameworks and clinical guidance while outlining the 2030 strategic priorities, including innovation in cancer treatment, real-world impact, prevention, survivorship and professional development.